Up to 40 percent of DNA results from consumer genetic tests might be bogus
A new study has found that direct-to-consumer genetic tests, like those marketed by 23andMe, Ancestry.com, Family Tree DNA, and MyHeritage, can be used to obtain innacurate results.
Data dump: Most of these tests use a technique called genotyping to provide information about a person’s ancestry, risk of developing certain disorders, or status as a carrier of specific diseases. Some companies also make the raw genotyping data available to customers upon request. People can then take that data to third-party companies to interpret for a fee.
Lost in interpretation: Scientists at Ambry Genetics, a diagnostics company that also interprets data from consumer DNA tests, looked at this raw genotyping data from 49 people. They found that 40 percent of the variants noted in the raw data were false positives—that is, they indicated that a particular genetic variant was present when it wasn’t. Most of the false-positive calls were of cancer-linked genes. In eight instances, third-party interpretation services misunderstood the variants present.
Buyer beware: Unlike clinical genetic tests that require a physician’s sign-off, direct-to-consumer tests are not meant to provide a diagnosis, and they offer risk information for only a limited number of conditions. If a consumer DNA kit uncovers a surprising or noteworthy genetic variant, the authors advise people to seek out doctor-ordered genetic tests to confirm the results.
Deep Dive
Biotechnology and health
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
A biotech company says it put dopamine-making cells into people’s brains
The experiment to treat Parkinson’s is a critical early test of stem cells’ potential to tackle serious disease.
Tiny faux organs could crack the mystery of menstruation
Researchers are using organoids to unlock one of the human body’s most mysterious—and miraculous—processes.
After 25 years of hype, embryonic stem cells are still waiting for their moment
Research roadblocks and political debates have delayed progress—but scientists are inching closer to delivering a cure.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.